This edition of the newsletter highlights the evolving urology surgery landscape in India, driven by a rising burden of urological disorders, increasing procedural volumes, and growing adoption of minimally invasive treatment options. The sector is witnessing strong momentum led by demand for kidney stone management, expanding prostate care interventions, and advancements in endourological and laparoscopic techniques. This report presents a concise overview of India’s urology market, covering disease burden, procedure trends, key drivers and challenges, and emerging opportunities.
Urological disorders affect an estimated 15–20% of India’s adult population, with kidney stones impacting nearly 12% of individuals during their lifetime; among the highest prevalence rates globally. India’s top 65 cities perform more than 14 lakh urological procedures annually, supported by over 1,200 urology-capable hospitals. However, access remains constrained, with fewer than three urologists available per million population. Kidney stone removal continues to be the largest procedure segment, accounting for approximately one-third of all urology procedures.
At the same time, prostate surgery remains significantly underpenetrated despite an estimated 2 lakh patients being eligible for TURP and other prostate interventions each year. Adoption is often limited by delayed diagnosis, treatment costs, and low awareness levels. Additionally, kidney stone recurrence rates remain high, with nearly 50% of patients experiencing recurrence within 5–7 years, driving sustained demand for repeat interventions. Minimally invasive procedures such as RIRS and PCNL are gaining traction, although overall penetration remains relatively low. Overall, the Indian urology surgery market reflects strong demand fundamentals with substantial headroom for growth, particularly in advanced minimally invasive and prostate care interventions.
Building on the strong demand fundamentals highlighted earlier, the Indian urology surgery market is being driven by the rising prevalence of kidney stone disease, prostate disorders, and urological cancers, alongside an ageing and increasingly urbanized population. Expanding urology OT infrastructure and growing private hospital investments across Tier 1 and Tier 2 cities are improving procedural capacity, while increasing awareness and early diagnosis through ultrasound and PSA screening are contributing to higher treatment volumes. Additionally, domestic manufacturing of endoscopes, laser systems, and lithotripters is helping reduce procedure costs, while government initiatives such as PMJAY (Ayushman Bharat) are improving access to urological care.
At the same time, the sector presents significant growth opportunities. Advances in wearables and AI-enabled imaging are supporting earlier detection and continuous management of urological conditions, creating opportunities for recurring care pathways. A large untreated population suffering from BPH and prostate cancer makes prostate surgery one of the most attractive long-term growth segments within urology. Furthermore, wider adoption of domestic laser technologies, expansion of specialist training programs, and broader insurance inclusion have the potential to unlock substantial growth in kidney stone management procedures.
However, several challenges continue to limit market expansion. High out-of-pocket treatment costs and inadequate insurance coverage remain major barriers to the adoption of advanced urological procedures. The shortage of trained urologists, particularly outside metropolitan areas, restricts access across Tier 2 and Tier 3 cities, while low awareness and social stigma surrounding urological conditions often result in delayed diagnosis and treatment. In addition, fragmented insurance policies leave many procedures inadequately covered, increasing the financial burden on patients and constraining overall procedural uptake. Despite these barriers, improving affordability, access, and awareness are expected to remain key enablers of future market growth.
Recent developments in India’s urology surgery market highlight strong momentum driven by technological innovation, strategic acquisitions, and growing investments in advanced surgical platforms. Domestic and global players are increasingly focusing on expanding their urology portfolios, reflecting the attractive long-term growth potential of the segment.
Indian MedTech company Meril strengthened its position in robotic-assisted surgery with the launch of the Mizzo Endo 4000 robotic system, supporting urology procedures through AI-powered 3D visualization and 5G-enabled telesurgery capabilities. At the same time, industry consolidation continues to reshape the market. Intersurgical’s acquisition of Teleflex’s Interventional Urology division expanded its global urology device footprint, while Healthium Medtech’s acquisition of Paramount Surgimed enhanced its capabilities in urology consumables and precision surgical devices. Additionally, Pristyn Care secured fresh funding to accelerate the expansion of its hospital network, with urology remaining one of its key focus specialties. Globally, PROCEPT BioRobotics reported strong growth driven by increasing adoption of its AI-enabled HYDROS robotic platform delivering Aquablation therapy for BPH treatment.
On the technology front, robotic-assisted and minimally invasive procedures continue to gain traction across the urology ecosystem. AI-guided robotic prostatectomy is improving surgical precision and reducing post-operative complications, while Aquablation therapy is emerging as a promising treatment option for benign prostatic hyperplasia (BPH). Advanced laser technologies such as the Thulium Fiber Laser (TFL) are enhancing kidney stone management through improved fragmentation efficiency and faster stone clearance. In parallel, the adoption of single-use flexible ureteroscopes is helping reduce infection risks and supporting wider acceptance of RIRS procedures. Emerging capabilities in telesurgery and remote robotic interventions, enabled by 5G connectivity, are also expanding the future scope of specialized urological care beyond major metropolitan centers.
Overall, these developments underscore a rapidly evolving urology landscape characterized by increasing adoption of robotics, AI-enabled surgical technologies, strategic industry consolidation, and continued investment in minimally invasive care; positioning India as a high-growth market for advanced urology interventions.
MedIQ by 1Lattice is a comprehensive hospital intelligence platform that enables MedTech leaders to take data-led decisions on procedure-driven demand and hospital readiness. It maps ~2,000 medium and large private hospitals across 65+ cities in India and delivers market sizing across 13 surgical specialties and ~60 sub-specialties, along with insights on surgical volumes, infrastructure, and utilization trends.
The platform provides in-depth analysis and competitive intelligence through comprehensive mapping of hospitals, including key parameters such as number of beds, operating theatres (OTs), and facility capabilities. It enables impact assessment by tracking procedure volumes and surgeon availability across specialties, while also supporting strategic planning through detailed insights into demand patterns and growth opportunities.
MedIQ offerings include a robust database of surgical procedures and surgeons across 13 major specialties, along with a detailed doctor-level dataset capturing qualifications, specialties, and practice locations. Additionally, it offers procedure-level mapping of surgical consumables and equipment, helping stakeholders understand value pools and product demand.
Overall, MedIQ serves as a one-stop solution for MedTech companies to drive sustainable growth through data-backed decision-making, market prioritization, and targeted commercial strategies across India’s hospital ecosystem.
